EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Pancreatic metastases: An updated narrative review of epidemiology, diagnosis and management illustrated by a rare case of pulmonary artery intimal sarcoma

Fátima Carrasco-Valero, Indra D. Sanoja-Fernández, Sara Custodio-Cabello, José Ramón Sevilla-Resúa, Sheherezade Gallego-Nieto, Maria Carmen Montero-Hernández, Beatriz Chacón-Ovejero, Luis Cabezón-Gutiérrez

Journal of Clinical and Translational Research · 2026-08-27 · 12 (5) · 026270063

DOI: 10.36922/jctr026270063 ↗
AbstractBibliografische Angaben

Abstract

Background: Pancreatic metastases (PM) account for 2%–5% of pancreatic neoplasms diagnosed clinically, while autopsy series report a 3%–12% prevalence, reaching 43% in advanced malignancy. This statistic suggests underdiagnosis of silent lesions mimicking primary pancreatic tumors, representing a major diagnostic challenge. Aim: This study aims to summarize evidence on PM etiology, diagnosis, and management,  as illustrated by an exceptional case of acute pancreatitis (AP) secondary to pulmonary artery intimal sarcoma (PAIS). Methods: A narrative review of the medical literature was conducted in June 2026 using PubMed/MEDLINE. Publications available up to January 2026 were reviewed, including electronic ahead-of-print publications. Relevant original studies, systematic reviews, pooled analyses, and clinical guidelines were reviewed, synthesized, and integrated with the case. Results: Renal cell carcinoma (RCC), which accounts for 30%–70% of reported PM in clinical and surgical series, is characterized by indolent biology and latency periods exceeding ten years. Sarcomas, which represent 4.3%–7.2% of reported PM, are biologically aggressive sources of PM. AP presentation is exceptionally uncommon and is a result of mechanical pancreatic duct obstruction. Endoscopic ultrasound-guided fine-needle biopsy is considered the diagnostic standard, with a 97.9% accuracy. Metastasectomy achieves a 76.6% five-year survival rate in RCC cases. In PAIS cases, AP has been reported to resolve following systemic chemotherapy; however, this temporal association should not be interpreted as evidence confirming the proposed pathogenic mechanism. Conclusion: PM should be considered in any pancreatic mass or AP of uncertain origin in patients with cancer. The oligometastatic disease model (≤5 lesions) supports curative-intent or prolonged systemic disease-control strategies. Relevance for patients: Accurate diagnosis prevents staging errors, preserves pancreatic function, and supports prolonged radiological surveillance in tumors with pancreatic tropism.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →